Charles L. Sawyers, MD
Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Dr. Sawyers examines how signaling pathway abnormalities in cancer cells can be exploited as targets for new cancer drugs. His research is best demonstrated through his earlier studies of BCR-ABL tyrosine kinase function in chronic myeloid leukemia (CML), his work in the development of the kinase inhibitor imatinib as the primary therapy for CML, and his discovery that imatinib resistance is caused by BCR-ABL kinase domain mutations. This discovery led Dr. Sawyers to evaluate second-generation ABL kinase inhibitors, such as the dual SRC/ABL inhibitor dasatinib, which received fast-track FDA approval. His current focus is on developing new treatments for patients with prostate cancer who have developed resistance to drugs that fight the cancer by blocking androgens.
Overcoming Resistance to Targeted Therapy
Charles L. Sawyers, MD, and Cancer Center Director Michelle Le Beau, PhD